Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
- PMID: 32027842
- DOI: 10.1016/S1473-3099(19)30634-6
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
Abstract
Background: The monoclonal antibody m102.4 is a potent, fully human antibody that neutralises Hendra and Nipah viruses in vitro and in vivo. We aimed to investigate the safety, tolerability, pharmacokinetics, and immunogenicity of m102.4 in healthy adults.
Methods: In this double-blind, placebo-controlled, single-centre, dose-escalation, phase 1 trial of m102.4, we randomly assigned healthy adults aged 18-50 years with a body-mass index of 18·0-35·0 kg/m2 to one of five cohorts. A sentinel pair for each cohort was randomly assigned to either m102.4 or placebo. The remaining participants in each cohort were randomly assigned (5:1) to receive m102.4 or placebo. Cohorts 1-4 received a single intravenous infusion of m102.4 at doses of 1 mg/kg (cohort 1), 3 mg/kg (cohort 2), 10 mg/kg (cohort 3), and 20 mg/kg (cohort 4), and were monitored for 113 days. Cohort 5 received two infusions of 20 mg/kg 72 h apart and were monitored for 123 days. The primary outcomes were safety and tolerability. Secondary outcomes were pharmacokinetics and immunogenicity. Analyses were completed according to protocol. The study was registered on the Australian New Zealand Clinical Trials Registry, ACTRN12615000395538.
Findings: Between March 27, 2015, and June 16, 2016, 40 (52%) of 77 healthy screened adults were enrolled in the study. Eight participants were assigned to each cohort (six received m102.4 and two received placebo). 86 treatment-emergent adverse events were reported, with similar rates between placebo and treatment groups. The most common treatment-related event was headache (12 [40%] of 30 participants in the combined m102.4 group, and three [30%] of ten participants in the pooled placebo group). No deaths or severe adverse events leading to study discontinuation occurred. Pharmacokinetics based on those receiving m102.4 (n=30) were linear, with a median half-life of 663·3 h (range 474·3-735·1) for cohort 1, 466·3 h (382·8-522·3) for cohort 2, 397·0 h (333·9-491·8) for cohort 3, and 466·7 h (351·0-889·6) for cohort 4. The elimination kinetics of those receiving repeated dosing (cohort 5) were similar to those of single-dose recipients (median elimination half-time 472·0 [385·6-592·0]). Anti-m102.4 antibodies were not detected at any time-point during the study.
Interpretation: Single and repeated dosing of m102.4 were well tolerated and safe, displayed linear pharmacokinetics, and showed no evidence of an immunogenic response. This study will inform future dosing regimens for m102.4 to achieve prolonged exposure for systemic efficacy to prevent and treat henipavirus infections.
Funding: Queensland Department of Health, the National Health and Medical Research Council, and the National Hendra Virus Research Program.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
A trial for post-exposure prophylaxis against henipaviruses.Lancet Infect Dis. 2020 Apr;20(4):387-388. doi: 10.1016/S1473-3099(19)30687-5. Epub 2020 Feb 3. Lancet Infect Dis. 2020. PMID: 32027841 No abstract available.
Similar articles
-
Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.Lancet Infect Dis. 2018 Aug;18(8):884-893. doi: 10.1016/S1473-3099(18)30397-9. Epub 2018 Jun 18. Lancet Infect Dis. 2018. PMID: 29929783 Clinical Trial.
-
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.Lancet Infect Dis. 2020 Apr;20(4):455-466. doi: 10.1016/S1473-3099(19)30614-0. Epub 2020 Jan 14. Lancet Infect Dis. 2020. PMID: 31952923 Clinical Trial.
-
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia.Lancet Infect Dis. 2024 Jun;24(6):639-649. doi: 10.1016/S1473-3099(24)00030-6. Epub 2024 Feb 23. Lancet Infect Dis. 2024. PMID: 38408457 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Current progress towards prevention of Nipah and Hendra disease in humans: A scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials.Trop Med Int Health. 2024 May;29(5):354-364. doi: 10.1111/tmi.13979. Epub 2024 Feb 28. Trop Med Int Health. 2024. PMID: 38415314 Review.
Cited by
-
Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein.Nat Commun. 2024 Aug 12;15(1):6892. doi: 10.1038/s41467-024-51066-6. Nat Commun. 2024. PMID: 39134522
-
Recent Advances in Immunological Landscape and Immunotherapeutic Agent of Nipah Virus Infection.Cell Biochem Biophys. 2024 Jul 25. doi: 10.1007/s12013-024-01424-4. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 39052192 Review.
-
A potent Henipavirus cross-neutralizing antibody reveals a dynamic fusion-triggering pattern of the G-tetramer.Nat Commun. 2024 May 21;15(1):4330. doi: 10.1038/s41467-024-48601-w. Nat Commun. 2024. PMID: 38773072 Free PMC article.
-
Structure and design of Langya virus glycoprotein antigens.Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2314990121. doi: 10.1073/pnas.2314990121. Epub 2024 Apr 9. Proc Natl Acad Sci U S A. 2024. PMID: 38593070 Free PMC article.
-
Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains.Nat Commun. 2024 Apr 6;15(1):2987. doi: 10.1038/s41467-024-47213-8. Nat Commun. 2024. PMID: 38582870 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
